RESEARCH MONOGRAPH · KDC-MN-062

Cerebrolysin

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

62/100

Porcine brain peptide hydrolysate with paradoxically strong clinical data, mechanism still murky

Cerebrolysin is genuinely strange. It's a hydrolysate of porcine brain tissue, standardized to contain a defined mix of low-molecular-weight peptides and free amino acids, and it's been a registered drug in Eastern Europe, Russia, and parts of Asia for decades. The clinical literature is much more substantial than the standard Western dismissal of it suggests, but the mechanism story is still genuinely incomplete and that tension is the interesting thing about this compound.

The clinical data is what gives us pause about writing it off. Multiple meta-analyses (Bornstein, Muresanu, the Cochrane review) on cerebrolysin in acute stroke, vascular dementia, and traumatic brain injury show consistent signal across thousands of patients. The CASTA trial in acute ischemic stroke and the CARS trials in stroke recovery are large enough and well-designed enough that the effect isnt easy to dismiss as publication bias.

The mechanism story is where things get murky. Cerebrolysin contains peptide fragments that may have neurotrophic activity (somatomedin-like factors, neurotrophin-receptor-modulating peptides), and there's animal work showing BDNF and GDNF upregulation, anti-apoptotic effects, and amyloid-beta clearance enhancement. The Hartbauer and Hutter-Paier papers describe specific molecular mechanisms but the connection between these molecular effects and the clinical outcomes remains poorly characterized.

What we like: the clinical data is unusually solid for a compound with such an unclear mechanism, the safety profile across decades of use is excellent, and the neurotrophic story has enough preclinical support to be plausible even if not fully proven.

What we dont like: the lot-to-lot variability inherent in a tissue-derived product is a real concern, the mechanism is still murky enough that interpreting any specific effect is hard, and the prion safety question (relevant for any porcine tissue product) requires specific manufacturing controls that vary by supplier.

Sourcing is genuinely a challenge. Few suppliers produce cerebrolysin to clinical-grade standards, the manufacturing process matters enormously, and the difference between research-grade and clinical-grade material can be substantial. Provenance documentation matters more here than for almost any other compound on this list.

For research, cerebrolysin is an unusual tool. It works in clinical models in a way the mechanism doesnt fully explain. That tension is itself scientifically interesting. Worth careful work, not casual experimentation.

Evidence: 75
Mechanism: 45
Reliability: 70
Safety: 65
Sourcing: 50
Value: 55
Signal: 70
Staying power: 65

Plain-language summary Intrigue 65 / 100

Cerebrolysin is a porcine brain peptide hydrolysate used in Europe and Asia for stroke recovery and dementia. It contains a complex mixture of small peptides and amino acids. Available only as injection. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Porcine brain peptide hydrolysate

A complex peptide hydrolysate prepared from porcine brain, marketed in many countries for stroke recovery, traumatic brain injury, and cognitive impairment with neurotrophic factor-mimetic activity.

Abstract

Cerebrolysin is a complex peptide hydrolysate prepared from purified porcine brain through enzymatic digestion, manufactured by EVER Pharma (Austria). The product contains short peptides (15 percent of dry weight) and free amino acids (85 percent), with biological activity attributed primarily to the peptide fraction. Cerebrolysin is approved as a medicine in over 50 countries (including most of Europe, Russia, China, and Latin America) for ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer disease; it is not approved in the United States. The product is administered by intravenous infusion or intramuscular injection (oral administration is ineffective due to peptide degradation). Mechanism is incompletely characterized but includes BDNF, NGF, and CNTF mimetic activity, anti-apoptotic signaling, and reduction of beta-amyloid pathology in animal models. Phase 3 trials in acute stroke (CASTA, CARS) and Alzheimer disease have produced mixed results with effect sizes in the modest range. Pharmacokinetics are poorly characterized due to the complexity of the active substance; the source monograph reports parenteral research volumes used in the published literature.

Mechanism of action

Complex peptide mixture with neurotrophic factor mimetic activity (BDNF, NGF, CNTF). Anti-apoptotic. Beta-amyloid reduction.

Reported research dose ranges

Reported research volumes in the parenteral literature span 5 to 60 mL depending on study protocol.

References

Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia (CASTA): a randomized, placebo-controlled trial. Stroke 2012.
Alvarez XA, et al. Cerebrolysin reduces microglial activation in vivo and in vitro. Lancet Neurol 2011.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-062

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Cerebrolysin

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs